Valeant Pharmaceuticals International (NYSE: VRX) is a global, science-based specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products, primarily in the areas of neurology, infectious disease and dermatology. Through its global infrastructure, Valeant develops and commercializes important treatments for patients worldwide. Valeant has made rapid strides under a new management team with a strategic vision and renewed focus on its specialty pharmaceuticals business. The company has implemented major changes in the areas of product management, business development, research and development, corporate governance and supply chain operations.

In 2005, Valeant total revenues were $823 million, including product sales of $731 million that were generated through 430 products and more than 2,300 SKUs. Based in Costa Mesa, California, Valeant employs 3,767 people globally.